Your privacy, your choice

We use essential cookies to make sure the site can function. We also use optional cookies for advertising, personalisation of content, usage analysis, and social media.

By accepting optional cookies, you consent to the processing of your personal data - including transfers to third parties. Some third parties are outside of the European Economic Area, with varying standards of data protection.

See our privacy policy for more information on the use of your personal data.

for further information and to change your choices.

You are viewing the site in preview mode

Skip to main content

Table 2 Distribution of antidiabetic drugs according to diabetes control, by survey period, CoLaus|PsyCoLaus study, Lausanne, Switzerland

From: Fifteen-year trends in diabetes drug management and control in French-speaking Switzerland

 

2003-06

2009-12

2014-17

2018-21

No

Yes

P-value

No

Yes

P-value

No

Yes

P-value

No

Yes

P-value

Sample size

173

101

 

177

103

 

130

138

 

111

84

 

Bivariate

            

 Insulin

37 (21.4)

13 (12.9)

0.104

45 (25.4)

18 (17.5)

0.139

31 (23.9)

23 (16.7)

0.171

21 (18.9)

15 (17.9)

1

 Biguanides

99 (57.2)

52 (51.5)

0.38

130 (73.5)

82 (79.6)

0.312

102 (78.5)

115 (83.3)

0.352

89 (80.2)

62 (73.8)

0.305

 Sulfonylureas

71 (41.0)

25 (24.8)

0.008

53 (29.9)

23 (22.3)

0.21

26 (20.0)

16 (11.6)

0.066

17 (15.3)

8 (9.5)

0.282

 Thiazolidinediones

19 (11.0)

9 (8.9)

0.682

20 (11.3)

7 (6.8)

0.294

2 (1.5)

5 (3.6)

0.448

1 (0.9)

1 (1.2)

1

 DPP4 inhibitors

-

-

 

21 (11.9)

4 (3.9)

0.029

40 (30.8)

28 (20.3)

0.051

39 (35.1)

19 (22.6)

0.081

 GLP1 analogues

-

-

 

-

-

 

1 (0.8)

1 (0.7)

1

4 (3.6)

3 (3.6)

1

 SGLT2 inhibitors

-

-

 

-

-

 

6 (4.6)

5 (3.6)

0.764

21 (18.9)

9 (10.7)

0.16

 Other

8 (4.6)

4 (4.0)

1

11 (6.2)

4 (3.9)

0.584

7 (5.4)

6 (4.4)

0.78

4 (3.6)

2 (2.4)

0.701

Multivariable

            

 Insulin

1 (ref)

0.46 (0.22–0.96)

0.038

1 (ref)

0.62 (0.32–1.18)

0.148

1 (ref)

0.66 (0.35–1.26)

0.208

1 (ref)

0.86 (0.40–1.86)

0.699

 Biguanides

1 (ref)

0.90 (0.53–1.50)

0.675

1 (ref)

1.29 (0.68–2.44)

0.44

1 (ref)

1.44 (0.74–2.80)

0.284

1 (ref)

0.64 (0.31–1.34)

0.238

 Sulfonylureas

1 (ref)

0.50 (0.28–0.89)

0.018

1 (ref)

0.65 (0.36–1.18)

0.157

1 (ref)

0.60 (0.29–1.22)

0.157

1 (ref)

0.61 (0.23–1.57)

0.304

 Thiazolidinediones

1 (ref)

0.98 (0.40–2.37)

0.959

1 (ref)

0.52 (0.20–1.37)

0.188

1 (ref)

2.67 (0.48–15.0)

0.264

1 (ref)

1.25 (0.07–22.1)

0.881

 DPP4 inhibitors

-

-

 

1 (ref)

0.27 (0.08–0.84)

0.024

1 (ref)

0.50 (0.28–0.90)

0.022

1 (ref)

0.57 (0.29–1.12)

0.103

 GLP1 analogues

-

-

 

-

-

 

1 (ref)

1.04 (0.06–17.5)

0.977

1 (ref)

1.26 (0.26–6.17)

0.773

 SGLT2 inhibitors

-

-

 

-

-

 

1 (ref)

0.87 (0.25–3.07)

0.827

1 (ref)

0.50 (0.21–1.22)

0.13

 Other

1 (ref)

0.75 (0.21–2.69)

0.664

1 (ref)

0.56 (0.16–1.92)

0.353

1 (ref)

0.61 (0.18–2.09)

0.433

1 (ref)

0.64 (0.10–3.94)

0.632

  1. -, no data. Results are expressed as number of participants (column percentage) for bivariate analyses and as odds ratio (95% confidence interval) for multivariable analyses. Bivariate analyses conducted using Fisher’s exact test and multivariable analyses conducted using logistic regression for each antidiabetic drug separately adjusting for age (continuous), marital status (alone, in couple), educational level (high, middle, low), smoking status (never, former, current), BMI categories (normal, overweight, obese), hypertension (yes, no) and presence of hypolipidemic drug treatment (yes, no)
Back to article page

Diabetology & Metabolic Syndrome

ISSN: 1758-5996

Contact us